Development of 1st-in-class personalized organometallic with a unique & innovative mode of action coupled with nanoparticle
Feroscan was set up in 2014 at the initiative of its four founders bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian, triple negative breast and NSCL cancers.Feroscan’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 11, 2019 | Grant | €480K | 1 | — | — | Detail |
Jul 13, 2018 | Seed | €353K | 1 | Groupe Azeden | — | Detail |
Jun 1, 2015 | Grant | €120K | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Groupe Azeden | Yes | Seed |
Agence National de la Recherche | — | Grant |
Paris Sciences et Lettres | — | Grant |